BRPI0819887A2 - métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno - Google Patents

métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno

Info

Publication number
BRPI0819887A2
BRPI0819887A2 BRPI0819887A BRPI0819887A BRPI0819887A2 BR PI0819887 A2 BRPI0819887 A2 BR PI0819887A2 BR PI0819887 A BRPI0819887 A BR PI0819887A BR PI0819887 A BRPI0819887 A BR PI0819887A BR PI0819887 A2 BRPI0819887 A2 BR PI0819887A2
Authority
BR
Brazil
Prior art keywords
patient
agents
treating
methods
stem cells
Prior art date
Application number
BRPI0819887A
Other languages
English (en)
Inventor
Paul Gearing David
Luigi Vairo Gino
Liqing Jin
Edgar Dick John
Jane Busfield Samantha
Original Assignee
Csl Ltd
Uniiversity Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd, Uniiversity Health Network filed Critical Csl Ltd
Publication of BRPI0819887A2 publication Critical patent/BRPI0819887A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0819887A 2007-12-06 2008-12-04 métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno BRPI0819887A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99681907P 2007-12-06 2007-12-06
PCT/AU2008/001797 WO2009070844A1 (en) 2007-12-06 2008-12-04 Method of inhibition of leukemic stem cells

Publications (1)

Publication Number Publication Date
BRPI0819887A2 true BRPI0819887A2 (pt) 2017-05-23

Family

ID=40717202

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819887A BRPI0819887A2 (pt) 2007-12-06 2008-12-04 métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno

Country Status (13)

Country Link
US (6) US20110052574A1 (pt)
EP (1) EP2231187A4 (pt)
JP (1) JP2011505386A (pt)
KR (1) KR20100094527A (pt)
CN (1) CN101896200A (pt)
AU (1) AU2008331436A1 (pt)
BR (1) BRPI0819887A2 (pt)
CA (1) CA2706337A1 (pt)
EA (1) EA201070687A1 (pt)
IL (1) IL205951A0 (pt)
MX (1) MX2010006213A (pt)
WO (1) WO2009070844A1 (pt)
ZA (1) ZA201003515B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
US8492119B2 (en) * 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
JP2013505968A (ja) * 2009-10-01 2013-02-21 シーエスエル、リミテッド フィラデルフィア染色体陽性白血病の治療方法
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
AU2011217728B2 (en) * 2010-02-17 2013-03-14 Csl Limited Compositions and methods for targeting type 1 interferon producing cells
AU2013200910B2 (en) * 2010-02-17 2015-06-11 Csl Limited Composition and methods for targeting type 1 interferon producing cells
CN102821815A (zh) * 2010-02-18 2012-12-12 Csl有限公司 慢性炎症状态的治疗
US8920803B2 (en) 2010-06-15 2014-12-30 Csl Limited Immunotherapeutic method involving CD123 (IL-3Rα) antibodies and immunostimulating complex
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
AU2012202125B2 (en) * 2010-08-17 2015-03-19 Csl Limited Humanized Anti-Interleukin 3 Receptor Alpha Chain Antibodies
AU2011253598B1 (en) * 2010-08-17 2012-01-19 Csl Limited Humanized anti-interleukin 3 receptor alpha chain antibodies
NZ702415A (en) * 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
US20160031996A1 (en) * 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
CN103740639A (zh) * 2013-09-02 2014-04-23 北京大学人民医院 构建人源化Ph染色体阳性急性淋巴细胞白血病小鼠模型的方法
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
KR20160111672A (ko) * 2015-03-17 2016-09-27 한밭대학교 산학협력단 규칙적으로 배열된 미세 부호를 포함하는 인쇄물에 대한 구동 시스템，방법 및 그 제작 방법
EP3280442A4 (en) * 2015-04-08 2018-10-31 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd123
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
US20180320136A1 (en) * 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP2021512103A (ja) 2018-01-31 2021-05-13 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN112042597B (zh) * 2020-07-22 2022-04-29 南京普恩瑞生物科技有限公司 一种双人源化肿瘤异种移植模型的构建方法
CN111920802B (zh) * 2020-09-11 2024-01-23 华侨大学 穿心莲内酯在制备防治成人t细胞白血病药物的应用
MX2023007901A (es) 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.
IL317227A (en) 2022-05-27 2025-01-01 Sanofi Sa Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering
TW202434305A (zh) 2022-11-17 2024-09-01 德商溫瑟克斯製藥公司 於腫瘤微環境中可裂解之抗體-藥物結合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177078B1 (en) * 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
ATE510855T1 (de) * 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof

Also Published As

Publication number Publication date
IL205951A0 (en) 2010-11-30
JP2011505386A (ja) 2011-02-24
EP2231187A4 (en) 2013-02-20
EP2231187A1 (en) 2010-09-29
CA2706337A1 (en) 2009-06-11
US20110052574A1 (en) 2011-03-03
US20170029515A1 (en) 2017-02-02
US20130230510A1 (en) 2013-09-05
AU2008331436A1 (en) 2009-06-11
EA201070687A1 (ru) 2010-12-30
CN101896200A (zh) 2010-11-24
ZA201003515B (en) 2011-08-31
KR20100094527A (ko) 2010-08-26
WO2009070844A1 (en) 2009-06-11
MX2010006213A (es) 2010-09-07
US20200207861A1 (en) 2020-07-02
US20180079818A1 (en) 2018-03-22
US20150152185A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
BRPI0819887A2 (pt) métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno
BRPI0821168A2 (pt) anticorpo, hibridoma, e, métodos para tratar doenças em um paciente e para tratar um paciente de transplante
BRPI0818963A2 (pt) Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0810208A2 (pt) Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer.
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
LTC2100614I2 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI0818287A2 (pt) células dendríticas manipuladas e usos para o tratamento do câncer.
CR10667A (es) Compositions and methods for diagnosing and treating cancer
IL196470A (en) Antagonist antibody for the treatment of cancer
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI0719195A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0820707A2 (pt) Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0716975A2 (pt) Agentes de peso precipitados para uso em fluidos de perfuração
BRPI0808814A2 (pt) Anticorpos monoclonais para o tratamento do câncer
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PH12012502226A1 (en) Il-1 binding proteins
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BR112013014522A2 (pt) anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]